SG11201911841PA - Topical formulations comprising montelukast and combinations with mussel adhesive proteins - Google Patents
Topical formulations comprising montelukast and combinations with mussel adhesive proteinsInfo
- Publication number
- SG11201911841PA SG11201911841PA SG11201911841PA SG11201911841PA SG11201911841PA SG 11201911841P A SG11201911841P A SG 11201911841PA SG 11201911841P A SG11201911841P A SG 11201911841PA SG 11201911841P A SG11201911841P A SG 11201911841PA SG 11201911841P A SG11201911841P A SG 11201911841PA
- Authority
- SG
- Singapore
- Prior art keywords
- montelukast
- combinations
- topical formulations
- mussel adhesive
- adhesive proteins
- Prior art date
Links
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 title 1
- 229960005127 montelukast Drugs 0.000 title 1
- 108010004563 mussel adhesive protein Proteins 0.000 title 1
- 239000012049 topical pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017091819 | 2017-07-05 | ||
| CN2018087058 | 2018-05-16 | ||
| PCT/CN2018/094441 WO2019007356A1 (en) | 2017-07-05 | 2018-07-04 | TOPICAL FORMULATIONS COMPRISING MONTELUKAST AND COMBINATIONS WITH MOLD ADHESION PROTEINS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201911841PA true SG11201911841PA (en) | 2020-01-30 |
Family
ID=64949737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201911841PA SG11201911841PA (en) | 2017-07-05 | 2018-07-04 | Topical formulations comprising montelukast and combinations with mussel adhesive proteins |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11672792B2 (enExample) |
| EP (1) | EP3648767A4 (enExample) |
| JP (1) | JP7288404B2 (enExample) |
| KR (1) | KR102785243B1 (enExample) |
| CN (3) | CN110312513B (enExample) |
| AU (1) | AU2018295944B2 (enExample) |
| CA (1) | CA3068818A1 (enExample) |
| MA (1) | MA52924A (enExample) |
| MX (1) | MX2020000029A (enExample) |
| MY (1) | MY201703A (enExample) |
| SG (1) | SG11201911841PA (enExample) |
| TW (1) | TWI874298B (enExample) |
| WO (1) | WO2019007356A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3648767A4 (en) * | 2017-07-05 | 2021-04-28 | Jiangyin Mucocare Pharmaceutical Co., Ltd | TOPICAL FORMULATIONS WITH MONTELUKAST AND COMBINATIONS WITH SHELL ADHESION PROTEINS |
| SI3678705T1 (sl) | 2018-09-14 | 2023-10-30 | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. | Konjugati montelukasta in peptidov |
| MA54707A (fr) * | 2019-01-10 | 2021-11-17 | Jiangyin Mucocare Pharmaceutical Co Ltd | Nouvelles formulations contenant des antagonistes des récepteurs des leucotriènes |
| MX2022003057A (es) * | 2019-09-14 | 2022-06-16 | Jiangyin Usun Pharmaceutical Co Ltd | Nuevos peptidos. |
| CN114929259A (zh) * | 2019-12-02 | 2022-08-19 | 艾缇亚(上海)制药有限公司 | 新型多功能寡肽 |
| CN114929283A (zh) * | 2019-12-02 | 2022-08-19 | 艾缇亚(上海)制药有限公司 | 肽和多糖的新缀合物 |
| BR112022015199A2 (pt) | 2020-02-03 | 2022-10-11 | Taro Pharma Ind | Formulações tópicas de montelucaste |
| US12233055B2 (en) | 2020-02-03 | 2025-02-25 | Taro Pharmaceutical Industries Ltd. | Topical Montelukast formulations |
| EP4228641A1 (en) | 2020-10-13 | 2023-08-23 | Diomed Developments Limited | Gel formulations comprising montelukast |
| CN114588267A (zh) * | 2020-12-04 | 2022-06-07 | 江苏恒瑞医药股份有限公司 | 一种含酰胺类局部麻醉药的药物组合物 |
| US20240165247A1 (en) * | 2021-03-17 | 2024-05-23 | Jiangyin Usun Pharmaceutical Co., Ltd. | New peptide conjugates |
| WO2022193186A1 (en) * | 2021-03-17 | 2022-09-22 | Jiangyin Usun Pharmaceutical Co., Ltd. | New diagnostic and therapeutic agents |
| TW202337464A (zh) * | 2021-08-06 | 2023-10-01 | 大陸商安利提沙（上海）製藥有限公司 | 免疫不全病症的新治療 |
| CN116421547A (zh) * | 2023-03-09 | 2023-07-14 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 一种孟鲁司特钠外用乳膏剂的制备及其在炎症性皮肤病中的应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2213989C (en) * | 1995-12-28 | 2007-05-29 | Yoshitomi Pharmaceutical Industries Ltd. | External preparation for topical administration |
| US20030207932A1 (en) | 2002-05-03 | 2003-11-06 | Morris Mann | Compositions that prevent post-traumatic hyperpigmentation and methods related thereto |
| ATE529125T1 (de) * | 2003-08-07 | 2011-11-15 | Healor Ltd | Pharmazeutische zusammensetzungen und verfahren zur beschleunigung der wundheilung |
| US6987170B1 (en) * | 2004-08-09 | 2006-01-17 | Battelle Energy Alliance, Llc | Cloning and expression of recombinant adhesive protein Mefp-1 of the blue mussel, Mytilus edulis |
| WO2007126865A2 (en) * | 2006-03-30 | 2007-11-08 | Patrin Pharma | Leukotriene antagonists via nasal drug delivery |
| CN1961867A (zh) | 2006-11-16 | 2007-05-16 | 徐英权 | 孟鲁司特钠的颗粒剂型 |
| WO2008106081A1 (en) * | 2007-02-26 | 2008-09-04 | Larry Schlesinger | Topical formulations containing leukotriene receptor antagonist and use for treatment or prevention of capsular contracture, scarring or hyperpigmentation |
| WO2008105803A1 (en) | 2007-02-26 | 2008-09-04 | Larry Schlesinger | Topical formulations containing leukotriene receptor antagonist and uses thereof |
| WO2009137555A1 (en) | 2008-05-06 | 2009-11-12 | Schlesinger S Larry | Topical and injectable formulations comprising leukotriene receptor antagonist and uses thereof |
| CA2653011A1 (en) * | 2008-12-03 | 2010-06-03 | Apotex Technologies Inc | Method and apparatus for packaging and dispensing pharmaceuticals |
| GB0915319D0 (en) | 2009-09-03 | 2009-10-07 | Sharma Anant | Combination medicament |
| CN101773503A (zh) | 2010-01-12 | 2010-07-14 | 北京华禧联合科技发展有限公司 | 一种白三烯拮抗剂和抗组胺药组合物 |
| CA2802853C (en) | 2010-06-16 | 2016-07-26 | Bruce Chandler May | Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation |
| CN102895661A (zh) * | 2011-07-28 | 2013-01-30 | 中国科学院上海药物研究所 | 靶向CysLT1的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途 |
| JP6200432B2 (ja) | 2011-12-26 | 2017-09-20 | エスケー ケミカルズ カンパニー リミテッド | モンテルカストまたはその薬学的に許容可能な塩を含む経口投与用フィルム |
| CN103239450B (zh) | 2012-02-07 | 2014-11-26 | 齐鲁制药有限公司 | 一种能快速溶出、稳定的孟鲁司特钠口服固体制剂及其制备方法 |
| EP3308835B1 (en) * | 2013-03-13 | 2020-01-01 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of traumatic injury |
| CN103655497B (zh) | 2013-12-18 | 2018-05-29 | 北京华禧联合科技发展有限公司 | 一种孟鲁司特钠口腔崩解片及其制备方法 |
| WO2016021599A1 (ja) * | 2014-08-04 | 2016-02-11 | 日東電工株式会社 | 液性免疫誘導促進用組成物及びワクチン医薬組成物 |
| CN105769825A (zh) | 2014-12-24 | 2016-07-20 | 广州朗圣药业有限公司 | 一种孟鲁司特钠的口腔膜剂及其制备方法 |
| CN105878215A (zh) | 2014-12-31 | 2016-08-24 | 天津康鸿医药科技发展有限公司 | 一种稳定的孟鲁司特口腔速溶膜及其制备方法和用途 |
| KR101892340B1 (ko) * | 2015-03-13 | 2018-08-27 | 경희대학교 산학협력단 | 몬테루카스트의 생체이용률을 개선시키기 위한 방법 |
| CN104784157B (zh) | 2015-04-04 | 2018-06-26 | 齐鲁制药有限公司 | 一种稳定的孟鲁司特口腔薄膜剂 |
| WO2017011983A1 (zh) * | 2015-07-20 | 2017-01-26 | 江阴市本特塞缪森生命科学研究院有限公司 | 贻贝粘蛋白用于皮肤和皮肤附属器官的防护 |
| BR112018000953A2 (pt) | 2015-07-20 | 2018-09-11 | Bengt I. Samuelsson Institute Of Life Science Research | produto de proteína adesiva de mexilhão e aplicações do mesmo na supressão de inflamações de pele |
| WO2017147067A1 (en) * | 2016-02-22 | 2017-08-31 | Board Of Regents, The University Of Texas System | Antimicrobial compositions and uses thereof |
| US10548837B1 (en) | 2016-05-04 | 2020-02-04 | Taro Pharmaceutical Industries Ltd. | Topical montelukast for treatment of atopic dermatitis |
| EP3648767A4 (en) * | 2017-07-05 | 2021-04-28 | Jiangyin Mucocare Pharmaceutical Co., Ltd | TOPICAL FORMULATIONS WITH MONTELUKAST AND COMBINATIONS WITH SHELL ADHESION PROTEINS |
| JP7742226B2 (ja) * | 2018-05-28 | 2025-09-19 | ジャンイン ユスン ファーマシューティカル カンパニー，リミテッド | 新たな医薬品使用 |
| SI3678705T1 (sl) * | 2018-09-14 | 2023-10-30 | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. | Konjugati montelukasta in peptidov |
| MA54707A (fr) * | 2019-01-10 | 2021-11-17 | Jiangyin Mucocare Pharmaceutical Co Ltd | Nouvelles formulations contenant des antagonistes des récepteurs des leucotriènes |
-
2018
- 2018-07-04 EP EP18827979.8A patent/EP3648767A4/en active Pending
- 2018-07-04 CN CN201880002883.6A patent/CN110312513B/zh active Active
- 2018-07-04 AU AU2018295944A patent/AU2018295944B2/en active Active
- 2018-07-04 CA CA3068818A patent/CA3068818A1/en active Pending
- 2018-07-04 SG SG11201911841PA patent/SG11201911841PA/en unknown
- 2018-07-04 MX MX2020000029A patent/MX2020000029A/es unknown
- 2018-07-04 KR KR1020207003363A patent/KR102785243B1/ko active Active
- 2018-07-04 JP JP2019572791A patent/JP7288404B2/ja active Active
- 2018-07-04 CN CN202210843681.2A patent/CN115300508A/zh active Pending
- 2018-07-04 MA MA052924A patent/MA52924A/fr unknown
- 2018-07-04 US US16/628,170 patent/US11672792B2/en active Active
- 2018-07-04 MY MYPI2020000043A patent/MY201703A/en unknown
- 2018-07-04 CN CN202110903665.3A patent/CN113491696A/zh active Pending
- 2018-07-04 WO PCT/CN2018/094441 patent/WO2019007356A1/en not_active Ceased
- 2018-07-05 TW TW107123334A patent/TWI874298B/zh active
-
2023
- 2023-05-01 US US18/310,020 patent/US20230404992A1/en not_active Abandoned
-
2024
- 2024-12-11 US US18/977,212 patent/US20250302818A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018295944B2 (en) | 2023-12-14 |
| TW201919633A (zh) | 2019-06-01 |
| KR102785243B1 (ko) | 2025-03-26 |
| CN110312513A (zh) | 2019-10-08 |
| MX2020000029A (es) | 2020-08-06 |
| KR20200039677A (ko) | 2020-04-16 |
| CN113491696A (zh) | 2021-10-12 |
| TWI874298B (zh) | 2025-03-01 |
| EP3648767A1 (en) | 2020-05-13 |
| CN110312513B (zh) | 2022-07-08 |
| AU2018295944A1 (en) | 2020-02-20 |
| MY201703A (en) | 2024-03-13 |
| CA3068818A1 (en) | 2019-01-10 |
| US20230404992A1 (en) | 2023-12-21 |
| MA52924A (fr) | 2021-04-28 |
| US20250302818A1 (en) | 2025-10-02 |
| US20210145819A1 (en) | 2021-05-20 |
| JP2020527134A (ja) | 2020-09-03 |
| CN115300508A (zh) | 2022-11-08 |
| JP7288404B2 (ja) | 2023-06-07 |
| US11672792B2 (en) | 2023-06-13 |
| EP3648767A4 (en) | 2021-04-28 |
| WO2019007356A1 (en) | 2019-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201911841PA (en) | Topical formulations comprising montelukast and combinations with mussel adhesive proteins | |
| EP3638700B8 (en) | Proteinaceous heterodimer and use thereof | |
| EP3647338A4 (en) | MACROMOLECULAR COMPOUND AND LIGHT EMITTING ELEMENT WITH USE THEREOF | |
| ZA201802003B (en) | Dual function proteins and pharmaceutical composition comprising same | |
| EP3369795A4 (en) | ADHESIVE COMPOSITION AND MELT ADHESIVE | |
| EP3235830A4 (en) | Interleukin 15 protein complex and use thereof | |
| EP3271436A4 (en) | Hot melt adhesive composition and use thereof | |
| SG11201800578YA (en) | Mussel adhesive protein product and application thereof in inhibiting catarrh | |
| EP3255059A4 (en) | Antimicrobial peptide wy-21 and use thereof | |
| ZA201904704B (en) | Topical cyclosporine-containing formulations and uses thereof | |
| EP3290441A4 (en) | RGMa BINDING PROTEIN AND USE THEREOF | |
| EP3688036A4 (en) | HETERODIMER PROTEIN AND USE OF IT | |
| EP3226844A4 (en) | Proteins and protein conjugates with increased hydrophobicity | |
| EP3350276A4 (en) | ADHESIVE COMPOSITION AND ARTICLE MADE THEREFROM | |
| IL268583A (en) | Preparations and methods for use on the skin | |
| EP3290489A4 (en) | Silicone adhesive composition and adhesive tape | |
| EP3489225A4 (en) | ANALOG OF VORTIOXETINE, ITS USE AND ITS PREPARATION | |
| EP3279209A4 (en) | Adhesive peptide and use therefor | |
| EP3554944B8 (en) | Insect elimination system and use thereof | |
| PL3173452T3 (pl) | Taśma klejąca i jej zastosowanie | |
| EP3604336A4 (en) | ANTI-EMAP II ANTIBODIES AND THEIR USES | |
| EP3325499A4 (en) | Novel peptide and use thereof | |
| EP3209697A4 (en) | Fn14-binding proteins and uses thereof | |
| HK40091844A (zh) | 双功能蛋白质和包含其的药物组合物 | |
| HK40097160A (zh) | 抗tim-3抗体及其用途 |